

1 **Title: Identification of a novel FUS/ETV4 fusion and comparative analysis with**  
2 **other Ewing sarcoma fusion proteins**

3  
4 Megann A. Boone<sup>1,2</sup>, Cenny Taslim<sup>2</sup>, Jesse C. Crow<sup>2</sup>, Julia Selich-Anderson<sup>2</sup>, Mike Watson<sup>3</sup>,  
5 Peter Heppner<sup>4</sup>, James Hamill<sup>4</sup>, Andrew C. Wood<sup>4,5</sup>, Stephen L. Lessnick<sup>1,2,6</sup>, Mark  
6 Winstanley<sup>4,5</sup>

7  
8 <sup>1</sup> Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, 43210,  
9 USA

10  
11 <sup>2</sup> Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at  
12 Nationwide Children's Hospital, Columbus, OH, 43205, USA

13  
14 <sup>3</sup> LabPLUS, Auckland City Hospital, Grafton, Auckland 1148, New Zealand

15  
16 <sup>4</sup> Starship Children's Hospital, Grafton, Auckland 1023, New Zealand

17  
18 <sup>5</sup> University of Auckland, Auckland CDB, Auckland 1010, New Zealand

19  
20 <sup>6</sup> Department of Pediatrics, The Ohio State University, Columbus, OH, 43210, USA

21  
22 **Running title:** Comparison of FET/ETS translocations in Ewing sarcoma

23  
24 **Keywords:** Ewing sarcoma, novel translocation, FUS/ETV4, FET/ETS, bone cancer

25  
26 **Financial support:** This work was supported by the National Institutes of Health award U54  
27 CA231461 to Stephen Lessnick.

28  
29 **To whom correspondence should be addressed:**

30 Stephen L Lessnick, MD, PhD  
31 Abigail Wexner Research Institute at Nationwide Children's Hospital,  
32 700 Children's Drive, WA5011, Columbus, OH, 43205, USA;  
33 Tel: +1 (614) 355-2633; Fax: +1 (614) 355-2927;  
34 Email: [stephen.lessnick@nationwidechildrens.org](mailto:stephen.lessnick@nationwidechildrens.org)

35  
36 **Conflict of interest disclosure statement:** Research reported in this publication was supported  
37 by the National Institutes of Health award U54 CA231641 to SLL. The content is solely the  
38 responsibility of the authors and does not necessarily represent the official views of the National  
39 Institutes of Health. SLL declares a competing interest as a member of the advisory board for  
40 Salarius Pharmaceuticals. SLL is also a listed investor on United States Patent No. US 7,939,253  
41 B2, "Methods and compositions for the diagnosis and treatment of Ewing's sarcoma," and United  
42 States Patent No. US 8,557,532, "Diagnosis and treatment of drug-resistant Ewing's sarcoma."  
43 This does not alter our adherence to *Cancer Research* policies on sharing data and materials.

44  
45  
46 **Notes about the manuscript:**

47 **Word count:** 2499

48 **Total number of figures:** 4 figures, 5 supplemental figures

49 **Total number of tables:** 2

50

51 **Abstract**

52 Ewing sarcoma is an aggressive pediatric bone cancer defined by a chromosomal translocation  
53 fusing one of the FET family members to a member of the ETS transcription factor family. To date,  
54 there have been seven reported translocations, with the most recent translocation reported over  
55 a decade ago. We now report the first identification of a novel translocation occurring between  
56 the *FUS* gene and ETS family member *ETV4* detected in a neonatal patient with Ewing sarcoma.  
57 Given its apparent rarity, we conducted an initial characterization of FUS/ETV4 function by  
58 performing genomic localization and transcriptional regulatory studies. We knocked down  
59 endogenous EWS/FLI in the A673 cell line, and expressed FUS/ETV4 in its stead, and performed  
60 CUT&Tag and RNA-sequencing analyses. We compared these data to similar “knock-  
61 down/rescue” analyses of other rare (non-EWS/FLI) Ewing sarcoma-associated translocation  
62 products. Through this comparative analysis in the same genetic background, we demonstrate  
63 significant similarities across these fusions, and in doing so, validate this novel FUS/ETV4  
64 translocation as a *bona fide* Ewing sarcoma translocation. This study presents the first genomic  
65 comparisons of the rare Ewing sarcoma-associated translocation products, and reveals that the  
66 FET/ETS fusions share highly similar, but not identical, genomic localization and transcriptional  
67 regulation patterns. These data provide insights into the roles of both the FET and ETS sides of  
68 these fusions, and provide a generic strategy to provide further strength to the notion that  
69 FET/ETS fusions are key drivers of, and thus pathognomonic for, Ewing sarcoma.

70

71 **Significance**

72 Identification and initial characterization of the novel Ewing sarcoma fusion, FUS/ETV4, expands  
73 the family of Ewing-fusions and extends the diagnostic possibilities for this aggressive tumor of  
74 adolescents and young adults.

75

## 76 Introduction

77 Ewing sarcoma is an aggressive bone- and soft tissue-associated cancer primarily diagnosed in  
78 children and young adults (1, 2). The disease is characterized by the presence of a chromosomal  
79 translocation that encodes fusions between the amino-terminal domain of a FET (FUS, EWSR1,  
80 and TAF15) protein to the carboxyl-terminal domain of an ETS (E26 Transformation-Specific)  
81 transcription factor family member. The most common chromosomal translocation, present in  
82 ~85% of cases, is the t(11;22)(q24;q12), that fuses the *EWSR1* gene to *FLI1* to encode the  
83 EWS/FLI fusion oncoprotein (1, 2). EWS/FLI functions as an aberrant transcription factor that  
84 uses its ETS domain to bind DNA and the EWS-portion to regulate gene expression. Following  
85 the identification of EWS/FLI nearly three decades ago, an EWS/ERG fusion was found in ~10%  
86 of cases, followed by five other fusions that are present in <1% of cases each: EWS/FEV,  
87 EWS/ETV1, EWS/ETV4, FUS/ERG, and FUS/FEV (3, 4). Each of these is believed to function as  
88 an aberrant transcription factor, primarily on the basis of their similar domain structure to EWS/FLI.  
89 Here, we report a novel eighth Ewing sarcoma fusion, FUS/ETV4, identified in a neonatal patient.

90  
91 The ETS protein family is a large group of transcription factors characterized by a highly-  
92 conserved DNA-binding domain, with structural variability outside of this region contributing to  
93 subfamily classification (5). The five ETS members identified in Ewing sarcoma fusions derive  
94 from two of these subfamilies: FLI, ERG, and FEV are members of the ERG subfamily, and ETV1  
95 and ETV4 of the PEA3 subfamily (1, 2, 5). It is believed that these ETS family members bind  
96 similar high-affinity target sequences in vitro, but whether they have similar genomic localization  
97 in the context of the Ewing sarcoma fusions is unknown. This is of particular interest given the  
98 neomorphic capability of EWS/FLI to bind and regulate genes via GGAA-microsatellites in the  
99 human genome.

100

101 The amino-terminal intrinsically-disordered regions (IDRs) of EWS and FUS have biophysical  
102 features that appear critical to the ability of FET/ETS proteins to bind DNA and regulate gene  
103 expression. These IDRs have self-association properties that mediate phase separation and/or  
104 “hub” formation (6, 7). These unique properties are likely critical for FET/ETS fusion oncoprotein-  
105 mediated reorganization of chromatin architecture, formation of transcriptional hubs, and  
106 recruitment of necessary transcriptional co-factors, such as the BAF complex, and are thus likely  
107 crucial for Ewing sarcomagenesis (1, 2).

108  
109 The vast majority of molecular studies of Ewing sarcoma fusions have focused on EWS/FLI, but  
110 there are few, if any, detailed analyses of other fusion proteins. While it makes logical sense that  
111 FET/ETS fusions will have similar biologic functions, this has not been formally demonstrated.  
112 This focus on EWS/FLI and relative lack-of-focus on the other Ewing fusions has significant  
113 impact on the clinical management of patients (8). The advent of next-generation sequencing has  
114 allowed for the ready identification of EWS-based and FUS-based fusion transcripts or genomic-  
115 rearrangements (9). These technological advances have made the identification of fusion partners  
116 easier, and simultaneously raised new questions as to how to apply this information to clinical  
117 care. As an example, a recent survey by the Children’s Oncology Group found that only ~35% of  
118 clinician respondents indicated that non-EWS/FLI FUS/ETS fusions should be classified as Ewing  
119 sarcoma (8). Importantly, a significant portion of respondents indicated they were unsure whether  
120 alternative FET/ETS fusions should even be used to diagnose Ewing sarcoma or to allow patients  
121 to be included in Ewing sarcoma clinical trials (8).

122  
123 We now report the initial identification of a novel FUS/ETV4 fusion in a patient with Ewing  
124 sarcoma, and perform genomic localization and transcriptional studies in an Ewing sarcoma A673  
125 knock-down/rescue model system. We used this same system to perform the first comparative  
126 analysis of other rare, non-EWS/FLI, fusions in Ewing sarcoma, and in doing so, we demonstrate

127 strong similarities between all of the fusions, demonstrating that they are indeed functionally  
128 similar. At the same time, we find some differences between FET/ETS fusions that might  
129 represent differences in DNA binding function and interplay between the FET- and ETS-portions  
130 of the fusions. These data support the conclusion that all FET/ETS translocations should be  
131 regarded as *bona fide* Ewing sarcoma translocations and clinically classified as such.

## 132 **Materials and Methods**

### 133 **Constructs and retroviruses**

134 Puromycin-resistant retroviral vectors encoding shRNAs targeting Luciferase (iLuc; sequence: 5'-  
135 GATCCCCCTTACGCTGAGTACTTCGATTCAAGAGATCGAAGTACTCAGCGTAAGTTTTTGG  
136 AAC-3") or the 3'-UTR of endogenous EWS/FLI mRNA (iEF; sequence: 5'-  
137 GATCCCCATAGAGGTGGGAAGCTTATTTCAAGAGAATAAGCTTCCCACCTCTATTTTTTGGG  
138 AC-3') were previously described (10, 11). FET/ETS fusions (containing amino-terminal 3xFLAG-  
139 tags) were cloned into pMSCV-Hygro (Invitrogen); sequence details provided in Supplementary  
140 Table 1.

141

### 142 **Cell culture methods**

143 HEK-293EBNA (Invitrogen) and A673 cells (ATCC), cultured for 1-6 weeks, in appropriate media  
144 and retroviruses produced and used for infection as described (10-12). STR profiling and  
145 mycoplasma testing are performed annually on all cell lines.

146

### 147 **Immunodetection**

148 Whole-cell protein extraction, protein quantification, and Western blot analysis was performed as  
149 previously described (10-12). Immunoblotting was performed using anti-FLAG M2 mouse (Sigma  
150 F1804-200UG) and anti- $\alpha$ -Tubulin (Abcam ab7291). Membranes were imaged using the LiCor  
151 Odyssey CLx Infrared Imaging System.

152

### 153 **qRT-PCR**

154 Total RNA was extracted from cells using the RNeasy Extraction Kit (Qiagen 74136). Reverse  
155 transcription and qPCR were performed using the iTaq Universal SYBR Green 1-Step Reaction  
156 Mix (BioRad 1725151) on a Bio-Rad CFX Connect Real-Time System. Primer sequences listed  
157 in Supplementary Table 2.

158

### 159 **CUT&Tag and Analysis**

160 CUT&Tag (Cleavage Under Targets and Tagmentation) was performed as described by (13) on  
161 two biological replicates of knock-down/rescue A673 samples using the anti-FLAG M2 mouse  
162 antibody (1:100, Sigma F1804-200UG), and sequenced on the Illumina HiSeq4000 platform.  
163 Reads were trimmed, de-duplicated using SAMTOOLS (RRID:SCR\_002105), aligned to hg19  
164 reference genome, spike-in normalized using DESeq2 (median ratio method,  
165 RRID:SCR\_015687), tracks were generated and averaged across biological replicates using  
166 Deeptools (RRID:SCR\_016366), and peaks were called using MACS (RRID:SCR\_013291),  
167 DiffBind (RRID:SCR\_012918), and DESeq2 (14-16). Peaks were called as significant with the  
168 following parameters: Irreproducible Discovery Rate of 0.01, FDR (False Discovery Rate) < 0.05,  
169  $\log_2(\text{fold-change}) > 3$  over control samples (iEF+Empty Vector), mean normalized counts > 80.  
170 Overlaps were determined using VennDiagram (RRID:SCR\_002414) and GenomicRanges  
171 (RRID:SCR\_000025) (17).

172

### 173 **RNA-sequencing and Analysis**

174 RNA-sequencing was performed on two biological replicates of knock-down/rescue A673 cell  
175 samples. TruSeq Stranded mRNA Kit (Illumina Cat. No. 20020594) was used to prepare cDNA  
176 libraries from total RNA and sequenced on Illumina HiSeq4000 to generate 150-bp paired-end  
177 reads. Reads were analyzed for quality control, trimmed, aligned to the human genome and  
178 analyzed for differential expression using FastQC (RRID:SCR\_014583), MultiQC  
179 (RRID:SCR\_014982), Trim\_Galore (RRID:SCR\_011847), STAR (RRID:SCR\_004463, version  
180 2.5.2b), and DESeq2 (16). Venn diagrams were created for differentially expressed genes for  
181 samples compared to control cells (iEF+Empty Vector) (FDR < 0.05).

182

### 183 **Statistical Analysis**

184 PCR data is presented as mean  $\pm$  SEM. Significance of soft agar assays was determined using  
185 a Student's t-test, or as otherwise noted; p-values  $<$  0.05 were considered to be significant.



## 186 **Results & Discussion**

### 187 **Identification of a novel FUS/ETV4 translocation**

188 An infantile patient presented with a left posterior mediastinal mass (Figure 1A). The mass  
189 occupied a significant portion of the left thoracic cavity and extensive intraspinal extension was  
190 observed from T3 to T8 without evidence of metastatic disease. A thoracic laminoplasty and  
191 resection of the intraspinal component was performed to manage the severely compressed spinal  
192 cord. The pathology of open biopsy specimens revealed classic Ewing sarcoma with sheets of  
193 small round blue-staining cells with no evidence of differentiation (Figure 1B). The tumor was  
194 CD99-positive in a diffuse membranous staining pattern (Figure 1C), and positive for nuclear  
195 NKX2-2 expression (Figure 1D). *EWS* rearrangement was not detected, so *FUS* break-apart FISH  
196 was performed and identified a rearrangement. Commercial molecular genetic testing revealed a  
197 translocation between the *FUS* locus on chromosome 16p11.2 and the *ETV4* locus on  
198 chromosome 17q21. This translocation encoded an in-frame fusion between exons 1-9 of *FUS* to  
199 exons 10-13 of *ETV4*. A literature search revealed the FUS/ETV4 translocation to be a novel  
200 fusion, previously unreported and undiscussed.

201

### 202 **FUS/ETV4 has similar binding and transcriptional functions to EWS/ETV4**

203 There were no cell lines nor patient-derived xenograft models available from the patient in which  
204 to analyze the transcriptional functions of FUS/ETV4. We therefore cloned FUS/ETV4 into a  
205 retroviral expression vector, and also cloned EWS/ETV4 as the most similar *bona fide* rare Ewing  
206 sarcoma fusion (Figure 2A). To allow for analysis in an isogenic background, we knocked-down  
207 endogenous EWS/FLI in A673 Ewing sarcoma cells and expressed either EWS/ETV4 or  
208 FUS/ETV4 fusion proteins through retroviral transduction (Supplemental Figure 1A-B).

209

210 We first compared genome-wide localization of FUS/ETV4 and EWS/ETV4 using CUT&Tag (13).

211 Both constructs were 3xFLAG-tagged and the use of the same anti-FLAG antibody for genomic

212 localization allowed the data to be compared directly, without the confounding effects of using  
213 different antibodies with different affinities and specificities. We found that FUS/ETV4 bound  
214 >12,000 loci and EWS/ETV4 bound >17,000 loci. Strikingly, >10,000 bound loci were shared  
215 between the two proteins, and over 80% of FUS/ETV4 peaks overlapped with those of EWS/ETV4  
216 (Figure 2B).

217  
218 We next asked whether FUS/ETV4 induced a similar transcriptional profile to EWS/ETV4.  
219 Consistent with the genomic localization studies, RNA-sequencing revealed that 87% of the  
220 genes regulated by FUS/ETV4 were also regulated by EWS/ETV4, although EWS/ETV4 again  
221 regulated more genes than FUS/ETV4 (Figure 2C). Both fusions were capable of binding and  
222 regulating genes previously documented as EWS/FLI targets, including those associated with  
223 both high-affinity and GGAA-microsatellite binding sites (Supplemental Figure 1C-D). Taken  
224 together, these data demonstrate that the novel FUS/ETV4 fusion has transcriptional function that  
225 are similar to EWS/ETV4, and thus supports its identity as a *bona fide* Ewing sarcoma fusion.

226  
227 **ERG- and FEV-based fusions have similar binding and transcriptional functions**

228 We recognized that the A673 knock-down/rescue system could be generalized to compare other  
229 understudied Ewing sarcoma fusion proteins, particularly those ETS-family members that have  
230 both EWS- and FUS-versions. We therefore compared EWS/ERG to FUS/ERG, and EWS/FEV  
231 to FUS/FEV (Figure 3A and Supplemental Figure 2A-B; NB: neither EWS/FLI nor EWS/ETV1  
232 have FUS-versions identified to date). We found that almost 13,000 bound loci were shared  
233 between EWS/ERG and FUS/ERG, with >80% of the EWS/ERG loci also bound by FUS/ERG  
234 (Figure 3B, left panel; NB: The higher number of FUS/ERG-bound loci likely reflects higher protein  
235 expression of FUS/ERG, see Supplemental Figure 2B). Similarly, EWS/FEV and FUS/FEV  
236 shared almost 15,000 bound regions, accounting for ~70% of the regions bound by both fusion  
237 proteins (Figure 3B, right panel).

238  
239 RNA-sequencing revealed an ~80% overlap between genes regulated by EWS/ERG and  
240 FUS/ERG and that each regulated >9,000 genes (suggesting that much of the “excess” FUS/ERG  
241 binding was not-functionally associated with gene regulation; Figure 3C, left panel). Similarly,  
242 EWS/FEV and FUS/FEV regulated ~5,600 genes in common, representing ~65% of the genes  
243 regulated by EWS/FEV and ~90% of genes regulated by FUS/FEV (Figure 3C, right panel).

244  
245 Taken together with the ETV4-fusion data above, the finding that EWS/ETS and FUS/ETS fusions  
246 bind similar loci and regulate similar sets of genes suggest that the EWS- and FUS-regions of the  
247 fusions are largely interchangeable, and strengthen the notion that tumors harboring these fusions  
248 should all be considered Ewing sarcomas.

249

#### 250 **EWS- and FUS-based fusions have similar binding and transcriptional functions**

251 The analyses above demonstrated that fusions with the same ETS domain bind and regulate  
252 gene expression in a similar manner regardless of whether the fusion partner is EWS or FUS. We  
253 next sought to determine if DNA binding and gene regulation would be similar in fusions that had  
254 the same amino-terminus (either EWS or FUS), but differed in their ETS domain. We compared  
255 EWS/ETV4, EWS/ERG, and EWS/FEV alongside EWS/FLI (the most common Ewing sarcoma  
256 fusion) as a group, and FUS/ETV4, FUS/ERG, and FUS/FEV as a group in the A673 knock-  
257 down/rescue system (Supplemental Figure 2A-B). The EWS/ETS fusions shared almost 9,000  
258 bound loci (Supplemental Figure 3A), and the FUS/ETS fusions shared >8,700 bound loci  
259 (Supplemental Figure 3B). RNA-sequencing showed similar trends, with >5,400 genes similarly  
260 regulated by each of the EWS/ETS fusions (Supplemental Figure 3C), and ~2,900 genes  
261 regulated by the FUS/ETS proteins (Supplemental Figure 3D).

262

263 **Global similarities across all FET/ETS fusions support the inclusion of all tumors**  
264 **harboring FET/ETS fusions as *bona fide* Ewing sarcomas**

265 Lastly, we asked whether the similarities in DNA-binding and transcriptional regulation we  
266 observed in each “class” of fusion (grouped based on ETS domain or on amino-terminal domain)  
267 would be observed across the entire group of FET/ETS fusions included herein. The data  
268 generated above was therefore analyzed *in toto*. Genomic localization revealed that over 6,600  
269 loci were similarly bound and that ~2,600 genes were similarly regulated by all fusion proteins  
270 tested (Figure 4A-B). These overlaps were highly significant ( $p < 2.2 \times 10^{-16}$ ). We again observed  
271 that all fusions bound and regulated both GGAA-microsatellite associated genes, and genes  
272 associated with high-affinity ETS binding sites (Supplemental Figures 4A-B and 5A-B). Taken  
273 together, these data support the assertion that all FET/ETS fusion proteins have similar  
274 capabilities to bind DNA and regulate gene expression.

275  
276 The most common fusion in Ewing sarcoma, EWS/FLI, has been extensively studied (1, 2, 18).  
277 This work has led to development of novel concepts for EWS/FLI protein function, including the  
278 function of the EWS-portion of the fusion as a transcriptional regulatory domain, likely through the  
279 assembly of transcriptional hubs via self-association properties, the ability of the EWS-portion to  
280 recruit transcriptional co-regulators, such as BAF and LSD1, and the ability of the fusion to alter  
281 chromatin architecture (1, 2, 6, 19). Undergirding these properties lies the ability of the fusion to  
282 localize to specific loci in the genome, including those harboring GGAA-microsatellites and/or  
283 high-affinity ETS binding sites, and to dysregulate gene expression ultimately resulting in the  
284 formation of Ewing sarcoma. Although additional Ewing sarcoma translocations have been  
285 identified, the analysis of these fusions has been rudimentary at best and investigators have  
286 simply assumed similar function based on similar structure. At face value this seems reasonable,  
287 but leaves many unanswered questions, such as if functional differences in the fusions exist that  
288 might result in some being more rarely associated with Ewing sarcoma, or whether there is a

289 critical interplay between fusion type and cellular background that is required for Ewing sarcoma  
290 development. Finally, the lack of important comparative analyses has allowed for confusion to  
291 arise in the clinical management of patients with likely Ewing sarcoma that harbor one of the rare  
292 translocations. Indeed, patients with rare translocations may not be offered entry onto clinical  
293 trials designed for patients with Ewing sarcoma and may therefore lead to subpar care (8).

294  
295 In this report, we describe the identification of a novel FUS/ETV4 patient translocation. We  
296 demonstrate that this fusion shares many of the DNA-binding and gene regulatory properties of  
297 other Ewing sarcoma-associated fusion proteins, including the well-studied EWS/FLI fusion.  
298 Through a large-scale comparison between variant Ewing fusions in an isogenic system, we find  
299 that all of the Ewing fusions analyzed share significant similarities in DNA-binding and gene  
300 regulation. These data support the notion that the novel FUS/ETV4 fusion reported here is a *bona*  
301 *fide* Ewing sarcoma translocation, and suggest that FET/ETS translocations bind and regulate  
302 similar target genes to mediate oncogenesis. Accordingly, these data support that tumors  
303 containing FET/ETS translocations should be clinically diagnosed as Ewing sarcoma tumors and  
304 justifies the inclusion of patients with these tumors in standard and experimental Ewing sarcoma  
305 treatment protocols, as well as clinical trials.

306

307

308

309

310

311

312

313

314 **Declarations**

315 **Ethics**

316 Nationwide Children's Hospital Institutional Review Board determined that this project was not  
317 classified as human subjects research and was therefore exempt from review.

318

319 **Acknowledgements**

320 We thank Dr. Susan Arbuckle, Children's Hospital at Westmead, Sydney, Australia, for assistance  
321 with NKX2-2 staining of tumor samples. We also thank Dr. Andrea K. Byrum, Dr. Emily R. Theisen,  
322 Dr. Jack Tokarsky, Ariunaa Bayanjargal, and Iftekhar Showpnil for thoughtful discussion  
323 concerning the hypothesis and methodology of the project, as well as copyediting this manuscript.  
324 Additionally, we would like to acknowledge the generosity of the patient's family for the use of the  
325 tumor sequencing information in this study.

326

327 **Authors Contributions**

328 MAB, SLL, and MW(instanley) are responsible for conceptualization of the project. For patient  
329 care, MW(instanley) was acting oncologist, MW(atson) was acting pathologist, PH was acting  
330 neurosurgeon, JH was surgeon responsible for local tumor control, and AW provided patient  
331 sequencing guidance. Methodology for laboratory studies was formulated by MAB and SLL.  
332 Investigation was performed by MAB, JCC, and JSA. Data analysis was performed by MAB and  
333 CT. Manuscript preparation was completed by MAB and reviewing and editing was performed by  
334 all authors. Funding acquisition and supervision completed by SLL.

335

336 **Availability of data**


337 The sequencing datasets generated and analyzed during the current study are available in the  
338 Gene Expression Omnibus and accessible at GSE173185. All other data generated or analyzed  
339 during this study are available from the corresponding author upon reasonable request.

## 340 References

- 341 1. Riggi N, Suva ML, Stamenkovic I. Ewing's Sarcoma. *N Engl J Med*. 2021;384(2):154-64.
- 342 2. Grunewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Alava E, Kovar H, et al. Ewing
- 343 sarcoma. *Nat Rev Dis Primers*. 2018;4(1):5.
- 344 3. Sankar S, Lessnick SL. Promiscuous partnerships in Ewing's sarcoma. *Cancer Genet*.
- 345 2011;204(7):351-65.
- 346 4. Ng TL, O'Sullivan MJ, Pallen CJ, Hayes M, Clarkson PW, Winstanley M, et al. Ewing
- 347 sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. *J*
- 348 *Mol Diagn*. 2007;9(4):459-63.
- 349 5. Sizemore GM, Pitarresi JR, Balakrishnan S, Ostrowski MC. The ETS family of oncogenic
- 350 transcription factors in solid tumours. *Nat Rev Cancer*. 2017;17(6):337-51.
- 351 6. Boulay G, Sandoval GJ, Riggi N, Iyer S, Buisson R, Naigles B, et al. Cancer-Specific
- 352 Retargeting of BAF Complexes by a Prion-like Domain. *Cell*. 2017;171(1):163-78 e19.
- 353 7. Chong S, Dugast-Darzacq C, Liu Z, Dong P, Dailey GM, Cattoglio C, et al. Imaging dynamic
- 354 and selective low-complexity domain interactions that control gene transcription. *Science*.
- 355 2018;361(6400).
- 356 8. Kinnaman MD, Zhu C, Weiser DA, Mohiuddin S, Hingorani P, Roth M, et al. Survey of
- 357 Paediatric Oncologists and Pathologists regarding Their Views and Experiences with
- 358 Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's
- 359 Oncology Group. *Sarcoma*. 2020;2020:3498549.
- 360 9. Machado I, Noguera R, Pellin A, Lopez-Guerrero JA, Piqueras M, Navarro S, et al.
- 361 Molecular diagnosis of Ewing sarcoma family of tumors: a comparative analysis of 560
- 362 cases with FISH and RT-PCR. *Diagn Mol Pathol*. 2009;18(4):189-99.
- 363 10. Johnson KM, Mahler NR, Saund RS, Theisen ER, Taslim C, Callender NW, et al. Role for
- 364 the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma
- 365 anchorage independent growth. *Proc Natl Acad Sci U S A*. 2017;114(37):9870-5.
- 366 11. Theisen ER, Miller KR, Showpnil IA, Taslim C, Pishas KI, Lessnick SL. Transcriptomic
- 367 analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel
- 368 transcriptional dependencies for oncogenesis. *Genes Cancer*. 2019;10(1-2):21-38.
- 369 12. Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, et al.
- 370 Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the
- 371 Endoplasmic Reticulum Stress Response. *Mol Cancer Ther*. 2018;17(9):1902-16.
- 372 13. Kaya-Okur HS, Wu SJ, Codomo CA, Pledger ES, Bryson TD, Henikoff JG, et al. CUT&Tag
- 373 for efficient epigenomic profiling of small samples and single cells. *Nat Commun*.
- 374 2019;10(1):1930.
- 375 14. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence
- 376 Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25(16):2078-9.
- 377 15. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based
- 378 analysis of ChIP-Seq (MACS). *Genome Biol*. 2008;9(9):R137.
- 379 16. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
- 380 RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550.
- 381 17. Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, et al. Software for
- 382 computing and annotating genomic ranges. *PLoS Comput Biol*. 2013;9(8):e1003118.
- 383 18. Lawlor ER, Sorensen PH. Twenty Years on: What Do We Really Know about Ewing
- 384 Sarcoma and What Is the Path Forward? *Crit Rev Oncog*. 2015;20(3-4):155-71.
- 385 19. Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, et al. Reversible LSD1
- 386 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing
- 387 sarcoma tumor growth. *Clin Cancer Res*. 2014;20(17):4584-97.




389 **Figure Legends**




390  
391 **Figure 1. Neonatal patient presenting with Ewing sarcoma tumor**  
392 (A) Coronal magnetic resonance imaging (MRI) scan revealed a left posterior mediastinal mass.  
393 (B) Hematoxylin and eosin staining of patient tumor biopsy revealed sheets of undifferentiated,  
394 mitotically active small, round blue cells with dispersed chromatin and minimal amphophilic  
395 cytoplasm (50  $\mu$ M scale bar depicted on image). (C) CD99 immunohistochemistry reveals diffuse  
396 membranous expression (50  $\mu$ M scale bar depicted on image). (D) NKX2-2  
397 immunohistochemistry shows diffuse strong nuclear immunoreactivity (50  $\mu$ M scale bar depicted  
398 on image).





399  
400 **Figure 2. EWS/ETV4 and FUS/ETV4 DNA-binding and transcriptional profile overlap reveals**  
401 **similar biological functions**


402 (A) Protein schematic of 3xFLAG-tagged (3F) EWS/ETV4 and FUS/ETV4 constructs. EWS is  
403 represented in light grey, FUS in dark grey, and ETV4 in light blue. Exons included in each fusion  
404 are noted. (B) Venn diagram overlap analysis performed on CUT&Tag-detected genomic  
405 localization data for EWS/ETV4 and FUS/ETV4 expressed in A673 knock-down/rescue cells, as  
406 compared to control cells (Control: iEF + Empty Vector; EWS/ETV4: iEF + EWS/ETV4;  
407 FUS/ETV4: iEF + FUS/ETV4) (N=2). The number of peaks uniquely bound by each construct or  
408 those that are similarly bound are indicated in the figure. Significance of overlap:  $p < 2.2 \times 10^{-16}$ .  
409 (C) Venn diagram analysis of RNA-sequencing results depicting significantly regulated genes for  
410 EWS/ETV4 and FUS/ETV4-expressing A673 knock-down rescue cells, as compared to iEF +  
411 Empty Vector control cells (N=2). Number of regulated genes for each construct is indicated in  
412 the figure. Significance of overlap:  $p < 2.2 \times 10^{-16}$ .



413  
 414 **Figure 3. Comparison of FET/ERG and FET/FEV fusions shows similar genomic**  
 415 **localization and transcriptional regulatory profiles**

416 (A) Protein schematic of 3xFLAG-tagged (3F) cDNA constructs, including EWS/ERG, FUS/ERG,  
 417 EWS/FEV, and FUS/FEV. EWS is depicted in light grey, FUS in dark grey, ERG in teal, and FEV  
 418 in indigo. Exons included in each fusion are noted. (B) Venn diagram overlap analysis of  
 419 CUT&Tag genomic localization data for the corresponding fusion protein listed after expression  
 420 in A673 knock-down/rescue cells (iEF + Construct), as compared to control cells (iEF + Empty


421 Vector) (N=2). Number of bound regions for each construct depicted in figure. Significance of  
422 overlap:  $p < 2.2 \times 10^{-16}$ . (C) Venn diagram overlap analysis of RNA-sequencing expression data  
423 for genes called as significantly regulated by the corresponding construct listed in A673 knock-  
424 down/rescue cells, as compared to control cells (iEF + Empty Vector) (N=2). Number of  
425 significantly regulated genes by each fusion listed in figure. Significance of overlap:  $p < 2.2 \times 10^{-}$   
426 <sup>16</sup>.



427  
428

429 **Figure 4. Analysis of DNA-bound regions and regulated genes by FET/ETS fusion proteins**  
430 **reveals significant overlap**

431 (A) Venn diagram overlap analysis of CUT&Tag genomic localization binding data of FET/ETS  
432 translocations in A673 knock-down/rescue cells (N=2). All bound regions are called as significant  
433 for the corresponding translocation as compared to control cells (iEF + Empty Vector).  
434 Significance of overlap:  $p < 2.2 \times 10^{-16}$ . (B) Venn diagram analysis of significantly regulated genes  
435 by corresponding FET/ETS translocations, as compared to control cells (iEF + Empty Vector)  
436 determined using RNA-sequencing (N=2). Significance of overlap:  $p < 2.2 \times 10^{-16}$ .



437  
438 **Supplemental Figure 1. EWS/ETV4 and FUS/ETV4 fusion proteins studied in A673 knock-**  
439 **down/rescue model system**

440 (A) Representative qRT-PCR results of endogenous EWS/FLI mRNA levels in A673 cells  
441 harboring the indicated constructs (iLuc: control shRNA; iEF: shRNA targets the 3'UTR of  
442 endogenous EWS/FLI). EWS/FLI mRNA values were normalized to RPL30 mRNA control values.  
443 Asterisks indicate samples are statistically different as compared to control iLuc + Empty Vector  
444 cells (p-value < 0.05, N=1). (B) Western blot of 3xFLAG-tagged EWS/ETV4 and FUS/ETV4  
445 protein expression in A673 cells. Membranes were probed with  $\alpha$ -FLAG or  $\alpha$ -tubulin (loading

446 control) antibodies. (C-D) CUT&TAG and RNA-sequencing peak tracks visualized for Empty  
447 Vector cells (iEF + Empty Vector), EWS/ETV4-containing cells, and FUS/ETV4-containing cells  
448 (N=2 for each sample). Example genes include those associated with both microsatellite (*PKP1*)  
449 and high-affinity (HA) site (*MARK2*)-regulated genes. Peak track scales are depicted on the left.

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465


466

467

468

469


470



471

472 **Supplemental Figure 2. Successful expression of FET/ETS fusion proteins in A673 knock-**  
473 **down/rescue model system**

474 (A) Representative qRT-PCR results determining endogenous EWS/FLI mRNA knock-down in  
475 A673 cells. iLuc + Empty Vector cells contain endogenous EWS/FLI mRNA, whereas iEF +  
476 Construct samples contain shRNA targeting the 3'UTR of endogenous EWS/FLI mRNA. All  
477 samples were normalized to RPL30 mRNA control samples. Statistical significance as compared  
478 to iLuc + Empty Vector is indicated by asterisks ( $p$ -value < 0.05,  $N = 1$ ). (B) Western blot analysis  
479 demonstrating protein expression of FET/ETS fusion proteins in A673 knock-down/rescue cells.  
480 Membranes were probed for protein expression ( $\alpha$ -FLAG) and a loading control ( $\alpha$ -tubulin).




481

482 **Supplemental Figure 3. Overlap of EWS/ETS and FUS/ETS fusions reveals similar DNA-**  
 483 **binding and transcriptional profiles**


484 (A-B) DNA-bound regions called as significant over background for the (A) EWS/ETS fusions and  
 485 (B) FUS/ETS fusions were overlapped (N=2 for each sample). Number of individually bound and  
 486 shared bound regions are indicated in each circle. Significance of overlap:  $p < 2.2 \times 10^{-16}$ . (C-D)  
 487 Venn diagram analysis depicts significantly regulated genes for (C) EWS/ETS and (D) FUS/ETS  
 488 fusion proteins. The number of genes regulated by each protein is indicated in the figure (N=2 for  
 489 each sample). Significance of overlap:  $p < 2.2 \times 10^{-16}$ .






490  
491 **Supplemental Figure 4. FET/ETS fusion proteins bind at known EWS/FLI response**  
492 **elements in Ewing sarcoma cells**  
493 (A-B) Representative peak tracks from CUT&Tag DNA-binding analysis are shown for Empty  
494 Vector (iEF + Empty Vector) A673 control cells, as well as A673 knock-down/rescue cells  
495 containing each of the FET/ETS fusions listed (N=2 for each sample). Examples of (A) GGAA-  
496 microsatellite (*VRK1*) and (B) high-affinity site (*BIRC2*) bound peaks typically associated with  
497 EWS/FLI function in Ewing sarcoma cells depicted here. Peak track scales displayed on the right.

A



B



498  
499 **Supplemental Figure 5. RNA-sequencing analysis reveals FET/ETS fusions regulate genes**  
500 **typically associated with Ewing sarcoma cells**

501 (A-B) Representative tracks of RNA-sequencing expression data from IGV are shown for Empty  
502 Vector (iEF + Empty Vector) and rescue samples (iEF + FET/ETS translocation) (N=2 for each  
503 sample). Examples of expression data are associated with EWS/FLI regulation in Ewing sarcoma

504 cells via (A) GGAA-microsatellite (*CAV2*) and (B) high-affinity site (*LIPH*). Peak tracks scales are  
505 depicted on the right.

506 **Supplemental Table 1. Sequence of FET/ETS cDNA Constructs**

507

<b>Translocation</b>	<b>FET Exons</b>	<b>FET Amino Acids</b>	<b>ETS Exons</b>	<b>ETS Amino Acids</b>
EWS/FLI1 EWSR1:NP_001156757.1 FLI1: NP_002008.2	1-7	1-265	7-9	242-452
EWS/ETV4 EWSR1:NP_001156757.1 ETV4: NP_001073143	1-7	1-265	9-13	271-484
FUS/ETV4 FUS: NP_004951.1 ETV4: NP_001073143	1-10	1-355	9-13	271-484
EWS/ERG EWSR1:NP_001156757.1 ERG: NP_891548.1	1-7	1-265	9-12	250-479
FUS/ERG FUS: NP_004951.1 ERG: NP_891548.1	1-7	1-255	9-12	250-479
EWS/FEV EWSR1:NP_001156757.1 FEV: NP_059991.1	1-10	1-347	2-3	18-238
FUS/FEV FUS: NP_004951.1 FEV: NP_059991.1	1-10	1-355	2-3	18-238

508

509 **Supplemental Table 1.** Sequence of FET/ETS protein-encoding cDNA constructs used for

510 manuscript, including corresponding exon and amino acid information. All translocations studied

511 here directly correlate to translocations identified and reported in the literature found in Ewing

512 sarcoma patient tumors.

513 **Supplemental Table 2. Sequences for primers used in qRT-PCR experiments**

Gene	Forward Primer	Reverse Primer
EWS/FLI	5'-CAGTCACTGCACCTCCATCC	5'-TTCATGTTATTGCCCAAGC
RPL30	5'-GGGGTACAAGCAGACTCTGAAG	5'-ATGGACACCAGTTTTAGCCAAC

514  
515 **Supplemental Table 2.** Sequences of primers used for qRT-PCR experiments to determine  
516 knock-down of endogenous EWS/FLI mRNA. RPL30 is used as a control to normalize data for  
517 all samples.